Advanced search
Publication Cover
Diabetes, Metabolic Syndrome and Obesity Volume 16, 2023 - Issue
Submit an article Journal homepage
177
Views
0
CrossRef citations to date
0
Altmetric
REVIEW

Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review

Alanoud AladelDepartment of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, 11451, Saudi ArabiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1441-607XView further author information
ORCID Icon,
Jamilah AljaouniDepartment of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, 11451, Saudi ArabiaORCID Iconhttps://orcid.org/0009-0000-1186-8268View further author information
ORCID Icon &
Reem BasaadDepartment of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, 11451, Saudi ArabiaView further author information
Pages 3381-3391 | Received 03 May 2023, Accepted 17 Oct 2023, Published online: 27 Oct 2023

References

  • Tilinca MC, Tiuca RA, Burlacu A, Varga A. (2021) A update on the use of liraglutide in the modern treatment of ‘diabesity’: a narrative review. Medicina. 2021;57(7):669. doi:10.3390/medicina57070669
  • Rana K, Ghimire P, Chimoriya R, Chimoriya R. Trends in the prevalence of overweight and obesity and associated socioeconomic and household environmental factors among women in Nepal: findings from the Nepal demographic and health surveys. Obesities. 2021;1(2):113–135. doi:10.3390/obesities1020011
  • Power ML, Schulkin J. Sex differences in fat storage, fat metabolism, and the health risks from obesity: possible evolutionary origins. Br J Nutr. 2008;99(5):931–940. doi:10.1017/s0007114507853347
  • World Health Organization. Obesity and overweight. World Health Organization. Available from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.Accessed April 17, 2022.
  • Zheng L, Deng F, Wang H, Yang B, Qu M, Yang P. (2021) prevalence and influencing factors of overweight and obesity among adult residents of Western China: a cross-sectional study. Int J Chronic Dis. 2021;2021:1–8. doi:10.1155/2021/9919443
  • Darand M, Hajizadeh Oghaz M, Hadi A, Atefi M, Amani R. The effect of cocoa/dark chocolate consumption on lipid profile, glycemia, and blood pressure in diabetic patients: a meta-analysis of observational studies. Phytother Res. 2021;2021:1–15.
  • Ladenheim E. 2015 liraglutide and obesity: a review of the data so far. Drug Des Devel Ther. 1867. doi:10.2147/dddt.s58459
  • Trenson L, Trenson S, van Nes F, et al. Liraglutide for weight management in the real world: significant weight loss even if the maximal daily dose is not achieved. Obes Facts. 2021;15(1):83–89. doi:10.1159/000520217
  • Perna S, Guido D, Bologna C, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016;28(6):1251–1257. doi:10.1007/s40520-015-0525-y
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  • Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
  • Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:4919. doi:10.1136/bmj.i4919
  • Harder H, Nielsen L, Thi TDT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-H energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27(8):1915–1921. doi:10.2337/diacare.27.8.1915
  • Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163–1172. doi:10.1111/j.1463-1326.2009.01158.x
  • Mensberg P, Nyby S, Jørgensen PG, et al. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes Obes Metab. 2016;19(2):172–180. doi:10.1111/dom.12797
  • Cantini G, Di Franco A, Samavat J, Forti G, Mannucci E, Luconi M. Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol Cell Endocrinol. 2015;402:43–50. doi:10.1016/j.mce.2014.12.021
  • Kadouh HC, Halawi H, Chedid V, et al. TU1921 - liraglutide treatment modulates regional body fat distribution in individuals with obesity. Gastroenterology. 2018;154(6):S–1054. doi:10.1016/s0016-5085(18)33527-3
  • Kieffer TJ, Francis Habener J. The glucagon-like peptides. Endocr Rev. 1999;20(6):876–913. doi:10.1210/edrv.20.6.0385
  • Echebiri VC. 2014 A systematic review of the effectiveness of liraglutide for the treatment of type 2 diabetes. Int J Community Curr Res. 2014;3(4):106–117.
  • Perna S, Rondanelli M, Astrone P, Grugnetti A, Solerte SB, Guido D. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence. 2016;407. doi:10.2147/ppa.s97383

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.